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1. ABSTRACT 
 
Type 2 diabetes mellitus (T2DM) is an extremely complex endocrine and metabolic disease, and 
the two major causes are impaired insulin secretion and increased insulin resistance in several 
organs and tissues. A non-human primate is an invaluable model for the study of human diseases 
due to their close genetic, anatomical and physiological similarities to humans. They are widely 
used in biomedical research aiming to elucidate the physiological and molecular mechanisms of 
different diseases, such as cardiovascular diseases, metabolic syndrome, age-related changes in 
metabolic parameters, obesity, T2DM, atherosclerosis etc. 
This entire project has different aims; the first is to confirm that baboons are a very suitable 
model for studying metabolic diseases such as cardiovascular diseases, metabolic syndrome, age-
related changes in metabolic parameters, obesity etc, and confirm baboons as a model in a 
physical activity studies related to improving health and well-being. In fact, the first study was 
conducted to evaluate the SenseWear
®
 Armband (SWA), a metabolic holter used in humans to 
estimate the resting and the total energy expenditure in baboon and verify his reliability to 
estimate energy expenditure during resting and different activities also in non-human primates. 
The second and more complex study was related to elucidate, at least in part, the effects of a 
continuous infusion of a medication for the treatment of T2DM (Exenatide) in a non-human 
primate, in a model with impaired β-cell function, reporting a insulin sensitizing effect in the 
Exenatide-treated group, an increase insulin sensitivity and β-cells function and decrease in total 
body weight. This type of research could be extremely valuable for helping to develop potential 
new treatments for T2DM. 
In conclusion, in the first study we demonstrated that the SWA is a reliable and simple method to 
estimate total energy expenditure (TEE) and resting energy expenditure (REE) in non-human 
primate, baboons, by placing it in the “metabolic jacket”. 
In the second study we found a powerful, direct, insulin sensitizing effect of EXE on normal 
glucose tolerant baboons.   
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These studies provide novel solid basis for further clinical trials aimed at preserving and 
supporting subjects with diabetes or at high risk of developing it.  
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2. INTRODUCTION 
Diabete mellitus is a group of metabolic diseases of multiple aetiologies characterized by 
hyperglycemia together with disturbances of carbohydrates, fat, and protein metabolism resulting 
from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of diabetes 
is associated with microvascular damage effecting, particularly, eyes, kidneys, nerves, and heart, 
together with an increased risk of macrovascular disease (1).  
Type 2 diabetes mellitus (T2DM) is an extremely complex endocrine and metabolic disease, 
overweight, obesity and physical inactivity are major contributors to the development of insulin 
resistance and impaired glucose tolerance (2, 3). Recent data published from the World Health 
Organization (WHO) indicated that: 
 347 million people worldwide have diabetes. 
 In 2004, an estimated 3.4 million people died from consequences of high fasting blood 
sugar. 
 More than 80% of diabetes deaths occur in low- and middle-income countries. 
 WHO projects that diabetes will be the 7th leading cause of death in 2030. 
 Healthy diet, regular physical activity, maintaining a normal body weight and avoiding 
tobacco use can prevent or delay the onset of type 2 diabetes mellitus. 
 Overt diabetes has diagnosed when one or more of the follow conditions are present: 
Criteria for the diagnosis of diabetes (4): 
 Glycated Hemoglobin (HbA1C ) ≥6.5%.  
OR 
 Fasting plasma glucose (FPG) ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric 
intake for at least 8 h. 
OR 
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 2-h plasma glucose ≥200mg/dL (11.1mmol/L) during an oral glucose tolerance test 
(OGTT). The test should be performed as described by the WHO, using a glucose load 
containing the equivalent of 75 g anhydrous glucose dissolved in water.* 
OR 
 In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random 
plasma glucose ≥200 mg/dL (11.1 mmol/L). 
The most important condition to avoid developing diabetes is the glucose homeostasis that in 
T2DM patient is compromised by two major causes: impaired insulin secretion, increased insulin 
resistance in several organs and tissues. 
Pancreatic β-cells are in a constant, dynamic, change state: the balance between islet neogenesis 
and apoptosis need to be maintained in order to avoid abnormalities in the insulin secretion. 
Glucotoxicity and lipotoxicity are among the acquired defects that can lead to impaired insulin 
secretion (5).  
Glucotoxicity of the islet can be defined as a non physiological and potentially irreversible β-cell 
damage caused by a chronic exposure to a supra-physiological glucose concentration (6). 
Reduction in β-cell mass in a condition of basal hyperglycemia con lead to a major impairment 
in insulin secretion. 
Regarding the mechanism by which lipotoxicity can impair β-cell function, the emerging 
evidence has suggested that long-chain fatty acyl-coenzyme A ( Co A) might be involved in the 
β-cell dysfunction the occurred after a prolonged exposure of free fatty acids (FFAs) inhibiting 
insulin secretion. Proinflammatory cytokines and leptin, produced by fat tissue, could also impair 
β-cell function and promote β-cell apoptosis (5, 6).  
Insulin resistance has been showed to involve several tissues summarized in the “ominous octet” 
by Prof. DeFronzo (7): liver, muscle, β- cell, fat cell, gastrointestinal tract, α-cell, kidney and 
brain.  
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 Liver:  insulin resistance is manifested by an overproduction of glucose at basal state 
despite hyperinsulinemia, and an impaired suppression of hepatic glucose production in 
response to food ingestion. 
 Muscle: there is impaired glucose uptake following a meal ingestion leading a 
postprandial hyperglycemia. 
 As long as β-cell are capable to compensate the insulin resistance increasing insulin 
secretion glucose tolerance remain normal; whereas, when β-cell start failing plasma 
glucose start to raise and leads to the onset of diabetes. 
 Lipotoxicity implicates deranges in adipocytes metabolism: fat cells are resistant to the 
antilipolytic effect of insulin, chronic increase in plasma free FFAs stimulate 
gluconeogenesis, fail process to secrete normal amounts adiponectin and enlarged fat cell 
are insulin resistance and have less fat storage capacity.  
 Incretin hormones glucagon-like peptide 1 and glucose-dependent insulinotropic 
polypeptide (GLP-1 and GIP) stimulate insulin secretion, suppress glucagon secretion, 
inhibit gastric emptying and reduce appetite; a defect in incretin response to ingestion of 
a meal lead to a paradoxical raise in plasma glucagon secretion and impaired suppression 
of hepatic glucose production.    
  Basal plasma glucagon concentration is elevated in T2DM patient that leads to increase 
basal rate of hepatic glucose production. 
 The ability of the kidneys to reabsorb glucose under hyperglycemia is augmented. 
 
 Lower posterior and upper posterior hypothalamic areas are key centers for appetite 
regulation, in T2DM patient the magnitude of the inhibiting response to following 
glucose ingestion is reduced, leading to increase hepatic insulin production and reducing 
muscle glucose uptake. 
 
There are several different states occurring between normal glucose tolerance and diagnosis of 
frank diabetes. Impaired glucose tolerance (IGT) and impaired fasting glycemia (IFG) are 
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intermediate conditions in the transition between normality to diabetes. People with IGT or IFG 
are at high risk of progressing to T2DM, although they can remain in those conditions for years 
before the onset of the disease. 
It is possible summarize the evolution of β-cell dysfunction and changes in metabolic parameters  
during the development of diabetes in 5 stages (8): 
1. Compensation: insulin secretion increases to maintain normoglycemia in the face of insulin 
resistance resulting from obesity, physical inactivity, and genetic predisposition. Β-cell mass is 
tightly maintained through a balance of β-cell birth and β-cell death, there is an increase in β-cell 
number and probably also β-cell hypertrophy. 
2. Stable adaptation: occurs when fasting glucose starts to rise between 5.0-7.3mmol/L. β-cell 
can no longer be considered to be compensating because truly normal glucose levels cannot be 
longer maintained, important changes in β-cell function and differentiation occur, acute insulin 
response (AIR) or fist phase is lost. 
3. Unstable early decompesation: glucose levels raise relatively rapidly from the range of 7.3 
mmol/L to higher values  16-20 mmol/L because of a critical decline on β-cell mass.  
4. Stable decomposition: is characterized by a stable decomp -
 50% is lost. 
5. Severe decomposition: profound reduction in β-cell mass so severe that people become ketotic 
and truly dependent on insulin to survive. 
Thanks to the progression of the treat of diabetes transition to stage 2 to stage 4 is reversible in 
T2DM patients with few changes in the lifestyle such as diet control, increasing physical activity 
and taking drugs. 
There are many medical issues that can be investigated and possibly solved with further research 
in rodents and humans. However, we believe that some of these issues can only be answered 
through experimental protocols in non-human primates because of their genetic and 
physiological similarities with humans as our group already showed (9-13). 
In both the experimental protocol completed we used non-human primates.  
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The first study was to evaluate the use of SenseWear
®
 Armband (SWA), a metabolic holter used 
in humans to estimate the resting and the total energy expenditure, in baboon and verify its 
reliability to estimate energy expenditure during resting and different activities also in non-
human primates.  
The second and more complex study was related to elucidate, at least in part, the effects of a 
medication for the treatment of T2DM (Exenatide) in an advanced state of the diabetes disease 
such as impaired β-cell function. We created a deficiency in insulin secretion by removing part 
of the pancreas, a procedure called a partial pancreatectomy. With this procedure we intend to 
prove that the amount of insulin released is decreased after the pancreatic surgery, and that 
specific pharmacological treatments might preserve insulin production and release, even in the 
presence of β-cell stress resulting from the surgery. The drug we used is the Exenatide (synthetic 
exendin-4), a medication approved from the United States Food and Drug Administration  (FDA) 
in 2005 and by the European Medicines Agency (EMA) in 2006 for the treatment of T2DM.  
In order to precisely measure the amount of insulin secreted, we created an acute increase in 
insulin secretory demand by a procedure called hyperglycemic clamp, where we administer a 
large amount of glucose intravenously in order to maintain a fixed plasma glucose concentration 
in the bloodstream of the baboons while measuring the corresponding response in insulin 
production. Before starting the study we expected to observe changes in insulin levels before and 
after the partial pancreatectomy and also hope to demonstrate that Exenatide improves β-cell 
function after partial pancreatectomy.  
This type of research is extremely valuable for helping to develop potential new treatments for 
T2DM. 
This work has different aims; the first is to confirm that baboons are a very suitable model for 
studying metabolic diseases such as cardiovascular diseases, metabolic syndrome, age-related 
changes in metabolic parameters, obesity, T2DM and atherosclerosis etc. 
The second is regarding baboons as a model in a physical activity studies related to improving 
health and well-being.   
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The third and most important goal is to elucidate the effects of a continuous infusion of 
Exenatide (synthetic exendin-4) in a non-human primate and the relative effects of the glucose 
metabolism, and body composition and relative implication for cure T2DM.  
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3. DIABETES 
Type 1- and Type 2 Diabetes Mellitus (T1DM, T2DM) are both characterized by a continuous 
loss of β-cell function paralleled by a progressive decline in β-cell mass (8, 14).  At the time of 
T2DM diagnosis, β-cell function is reduced to ~ 50% and β-cell mass to ~ 60% (15).  In T1DM 
the deficit in β-cell mass is more severe and averages 70-100% (16).  Interestingly, a dimorphic 
histology of long-lasting T1DM has been reported, with 70% of subjects showing only insulin-
deficient islets while 30% numerous insulin-positive cells (17). Indirect evidence of the 
persistence of residual β-cells 30-40 years after T1DM onset has been recently achieved by using 
an ultrasensitive C-peptide assay (18).  
Different pharmacological interventions have been explored to prevent or reduce the loss of β -
cell function and mass in the effort to arrest the progression of these diseases. Unfortunately, as 
shown by the UKPDS study (19, 20), conventional anti-diabetic drugs do not address this goal 
and some can actually lead to β-cell death (21).  Conversely, more recently developed drugs such 
as thiazolidinediones (TZD) and glucagon-like peptide 1 (GLP-1) receptor agonists have been 
shown to induce significant β-cell protection (6).  Synthetic long-acting GLP-1 receptor agonists 
(Exenatide and Liraglutide) exhibit glucoregulatory activities similar to the mammalian incretin 
GLP-1. These actions include glucose-dependent enhancement of insulin secretion and 
suppression of glucagon secretion, slowing gastric emptying, reduction of food intake and their 
clinically effectiveness has been widely demonstrated (3, 22, 23). In addition, GLP-1 receptor 
agonists show also protective effects on the β-cells, including reduction of apoptosis and 
enhancement of proliferation and neogenesis (23-27).  
However, the vast majority of these studies were performed on rodents and considerably less 
information is available on human tissues (28, 29).  In-vitro, GLP-1 receptor agonists exert anti-
apoptotic effects on human β-cells (30, 31) and inhibit the apoptosis induced by inflammation, 
glucotoxicity, lipotoxicity and reactive oxygen species (32-36).  Yet, it remains essentially 
unknown whether GLP-1 receptor agonists can cause β-cell growth in-vivo in humans or non-
human primates. 
We and Others have shown that baboons are an excellent animal model for the study of insulin 
resistance, obesity, and T2DM (9-11, 37).  Baboons share 96% genetic similarities with humans. 
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In baboons physical inactivity and overfeeding induce obesity, insulin resistance (10, 37) and 
spontaneous diabetes which is phenotypically identical to human disease (11).  Islets of 
spontaneously diabetic baboons show the same pathological features (i.e. amyloid deposits) of 
human T2DM pancreases (9).  Because of these remarkable similarities, we further exploited this 
preclinical model to study the effects of the chronic administration of the GLP-1 receptor agonist 
exenatide (EXE) on body composition, glucose metabolism, and insulin secretion fate in normal 
glucose tolerant (NGT) baboons.  We could then demonstrate that treatment with EXE induces in 
this model: - (i) a dramatic increase in insulin sensitivity; - (ii) a compensatory reduction of 
insulin and C-peptide secretion in response to acute glucose and arginine stimulations. We 
believe that these findings provide novel worthy rationales for the use of EXE in diabetes 
prevention and treatment.  
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4. INCRETIN HORMONES 
This study aims to look at the effects of glucagon-like peptide-1 (GLP-1) analogue, exendin-4 
(Exenatide), on several aspects involved in the development of diabetes, using an animal model.  
Incretins are hormones secreted by the gut endocrine cells in response to meals ingestion.  The 
most important incretin hormones are glucose-dependent insulintropic polypeptide (GIP) and 
glucagon-like peptide (GLP-1). Incretin hormones stimulate insulin secretion, suppress glucagon 
secretion, inhibit gastric emptying, and reduce appetite and food intake. The “incretin effect” 
refers to amplification of insulin secretion by hormones secreted from the gastrointestinal tract. 
Both rapidly stimulate the release of insulin only when glucose level is elevated, thereby 
enhancing the glucose–sensing and insulin secretory capacity of the endocrine pancreas during 
postprandial hyperglycemia. (38).  
GIP is a 42 amino acid peptide produced predominantly by duodenal and jejunal enteroendocrine 
K cells in the proximal small intestine; at fasting state the level is low and increases in few 
minutes after the ingestion of food. GLP-1 is a 30 amino acid incretin hormones produced by 
enteroendocrine L cells in the distal ileum and colon, and, similar to GIP, its level increases after 
food ingestion (6). Both GIP and GLP-1 contain alanine in position 2 and are degraded rapidly 
by dipeptidyl peptidase-4 (DPP-4); furthermore, they are cleared very quickly from the 
circulation via the kidney. 
 
4.1 GPL-1 AND EXENATIDE 
GLP-1 acts enhancing glucose-dependent stimulation of insulin secretion, it controls glucose 
levels by inhibition of glucagon secretion, and it has an inhibiting effect on gastric emptying and 
reduces the appetite and food intake. Moreover, GLP-1 has a control on the blood glucose level 
by inhibiting glucagon secretion, suppression hepatic glucose production and decreasing the 
gastric emptying process; lastly, it influences the central nervous system for the control of satiety 
(6). 
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The biological half-life of this hormone is around 2 minutes, and it is degraded by the enzyme 
DPP-4. GLP-1 mimetics and incretin enhancers (DPP-4 inhibitors) are a new class of drugs used 
for the treatment of T2DM. (32)  
GLP-1 has numerous effects on different parts of the body, acts directly on the endocrine 
pancreas increasing insulin biosynthesis and beta cell proliferation and reducing apoptosis; on 
the heart improving myocardial function and cardiac output, on the brain has a neuroprotection 
effect and reduce the appetite, and on the stomach GLP-1 has a reducing gastric emptying. 
Whereas GLP-1 acts on liver and muscle indirectly, it may mediate its effects on glucose control 
independent of insulin secretion through activation of peripheral sensors linked to enhanced 
glucose disposal in the muscle and inhibiting glucose production in the liver.  
All the physiological actions of GLP-1 are summarized in Figure 4.1.1. 
 
Figure 4.1.1 – GLP-1 actions in peripheral tissues. Figure from  Drucker DJ. The biology of incretin hormones. 
Cell metabolism. 2006;3(3):153-65 (39).  
Using incretin hormones in treatments for T2DM is very promising; it has been shown to have 
good results on glycemic profile, insulin sensitivity and β-cell function. 
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In our studies, we used Exenatide (Amylin Pharmaceuticals, CA) that is a synthetic exendin-4; it 
is a GLP-1 receptor agonists that have been developed to mimic the insulino-tropic 
characteristics of endogenous GLP-1 and to resist DPP-4 degradation.(40, 41). 
Exendin-4 is a 39 amino acid GLP-1 receptor agonist originally isolated from the Gila Monster’s 
(Heloderma suspectum ) saliva, that shares about 50% sequence of homology to GLP-1, it is a 
potent agonist for GLP-1 receptor stable against DPP-4 because contains a glycine residue in 
position 2 ,thereby conferring resistance to cleavage by DPP-4. Exendin-4 mimics all the 
glucose-lowering actions of GLP-1. (39). 
Several studies reported the acute effect of GLP-1 and GLP-1 receptor agonist on β-cell that is 
the potentiation of glucose-dependent insulin release found in animal models and humans (6, 
38). The chronic administration of incretins lead to the stimulation β-cell proliferation, induces 
islet neogenesis associated with increased β-cell mass and inhibition of β-cell apoptosis (6); 
moreover, it shows positive effects inhibiting gastric emptying, decreasing body weight and 
appetite in humans (3, 27, 42). 
Exenatide has been used in different studies, with positive effects on lowering HbA1c in all 
treatment groups by about 0.9%, nausea was the principal side effect reported (43-45); 
furthermore, it has been shown to decrease concentration of plasma glucose, fructosamine, and 
free fatty acids as well as it to improve insulin sensitivity and beta cell function in patient with 
T2DM (42). 
In diabetic patients a continuous administration of GLP-1 lowers blood glucose either at fasting 
then after food ingestion via inhibition of gastric emptying and glucagon secretion, and 
stimulation of insulin secretion, decreasing HbA1c, fructosamine, and free fatty acids (39, 42, 
46).  It is also shown that in T2DM patients GLP-1 markedly improves early- and late-phase 
insulin responses.(42). Moreover, in a recent meta-analyses published by Vilsboll et al., the 
results indicate that a treatment with GLP-1R agonists helps to reduce body weight in patient 
overweight and obese, with beneficial effects on systolic and diastolic blood pressure (3). 
Exenatide has effects also on adipocytes, has been shown that induces the expression of 
adiponectin and simultaneously inhibits proinflammatory adipokines (47), and it has anti-
inflammatory properties on the pancreas islets (32).  
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5. NON-HUMAN PRIMATES 
5.1 INTRODUCTION 
Non-human primates (NHP) are invaluable models for the study of human diseases due to their 
close genetic, anatomical and physiological similarities to humans. They are widely used in 
biomedical research aiming to elucidate the physiological and molecular mechanisms of different 
diseases, such as cardiovascular diseases, metabolic syndrome, age-related changes in metabolic 
parameters, obesity, T2DM and atherosclerosis etc. (48-51). 
Common baboons (Papio sp.) and macaques (Macaca sp.) are the most studied amongst Old 
World monkeys (Cercopithecoidea). In fact, the evolutionary divergence between Hominoidea 
(humans and apes) and Old World monkeys occurred relatively recently (~ 25 million years ago) 
and in fact Old World monkeys share great genetic similarities (96 % homology evident at the 
DNA level) with humans (10, 52).  
Baboons (Papio hamadryas) are characterized as relaxed and highly adaptable primates that have 
been largely studied in the wild and have been used in research for over 50 years (53). They are 
quadrumanal (pollux and hallux opposable), diurnal and mainly terrestrial with predominant 
quadrupedal locomotion, have a dense coat of hair, a short or medium-long tail; they are sexually 
dimorphic (weight and height of these animals is different between species and gender) (54, 55) 
(Figure 5.1.1). 
 
Figure 5.1.1.  Baboon (Papio hamadryas) at Southwest Foundation for Biomedical Research. This picture is a kind 
gift from Dr. Bill Cummins, Associate Director, and Veterinary Resources at the Southwest National Primate 
Research Center. 
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Baboons are primarily herbivorous, but they can also be omnivorous, eating small mammals and 
insects, birds, hares, fish and shellfish. Their average lifespan of   ~25 years makes them one of 
the longest lived primates, which can be maintained in controlled conditions for generations in 
order to study the effect of genetic and environmental factors (9, 10, 53). 
Baboons are a valuable research model in different medical fields. They are used as research 
models for osteoporosis, dyslipidemia, atherosclerosis, nutrition, aging, obesity and insulin 
resistance (9, 10, 13, 52, 53, 56-60). There are many medical issues that can be investigated and 
possibly solved with further research in rodents and humans. However, we believe that some of 
these issues can only be answered through experimental protocols in non-human primates 
because of their genetic and physiological similarities with humans. 
Reduction of caloric intake generally improves glucose metabolism and life span through 
improved insulin sensitivity in rhesus monkeys (61). Also, increasing the caloric expenditure 
through exercise can have a positive effect, in the treatment of human obesity and T2DM and 
other diseases (62, 63). 
Regular physical activity has been reported to decrease the risk of a numbers of major chronic 
diseases (64, 65). 
T2DM is one of the major health problems in our society and the incidence of this disease is 
increasing, currently being the sixth cause of death in the United States (59, 66). 
In nature, there is actually no single animal that can replicate the features of T2DM in humans; 
however, all the actual models (e.g. rodents, cats, dogs, pigs, and nonhuman primates) offer a 
rich range of opportunities to explore the numerous complexities of T2DM in its facets (58, 66-
68).  
In obese and old non-human primates the risk of developing diabetes is high similar to humans 
and they display biochemical features in whole body insulin resistance and a variety of  insulin 
signaling defects in muscle, adipose tissue and liver, during the progression of the disease. 
Furthermore, pathological changes in the islet of Langerhans, where there was a complete 
replacement of the islet with an islet-associated amyloid, composed of islet amyloid polypeptide 
(IAPP), are also speculate to ones seen in patients with T2DM (9, 13, 52, 69, 70).  
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Another very important non-human primate model of obesity, insulin resistance and T2DM is the 
rhesus that has been extensively characterized by the group of Barbara Hansen (71).  
5.2 NON- HUMAN PRIMATES IN BIOMEDICAL RESEARCH. 
Exercise is recommended to improve fitness, decrease body weight, and reduce the risk of 
complications of chronic diseases such as obesity, metabolic syndrome and T2DM (72, 73). 
Therefore, exercise physiology related research is highly relevant to the study of metabolic 
disease.  
Non-human primates have been used in different types of research where physical activity was 
utilized as a potential intervention to decrease the risk of developing overt diabetes (59). 
Previous studies have assessed the effect of exercise in different organs and systems, such as 
central nervous system (CNS) activity, reproductive organs, nutrition and bone physiology and 
its effects on body composition. In this regard, in a pilot study Garcia et al (54) showed that 
morphometrics and isotope-labeled water can be an appropriate method to study the body 
composition in baboons. In normal baboons studies they found an average water content of 66% 
similar to the one previously observed from other studies using different methods, an average fat 
free mass of about 90% and an average body fat less than 10%. Interestingly, the water content 
in baboons female is higher than that in woman and reflects the lower body fat in baboons 
compared to normal women.  
At this time there is an increasing interest in studying the contribution of physical activity levels 
to body weight regulation and body composition. Many of these studies are performed on human 
subjects, but non-human primate models could help to further understand the molecular 
mechanisms that occur in humans. 
Accelerometers, devices designed to register body movements in any direction have been used to 
monitor physical activity and consequently estimate energy expenditure (74). Multiple protocols 
with accelerometers have been used in humans. These devices have been also used in baboons. 
In different studies this device has been placed and tested in collars, implanted subcutaneously or 
placed in a jacket worn by the animals (64, 65, 75, 76).  However,  there are others traditional 
methods well studied in humans such as Double Labeled Water (DLW) (54), indirect calorimetry 
(IC) with calculation of Respiratory Quotient (RQ) (60). These techniques could be potentially 
applied to baboons and other non-human primates to calculate energy expenditure, but they are 
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expensive and quite complicated by the fact that they required an active collaboration of the 
study subject. 
New devices called activity monitors are now on the market. Using different mechanisms and 
software these devices calculate the amount of energy employed in different kinds of activity 
during the day and they can be worn for several days. These monitors can be useful tools to 
measure the total energy expenditure during free living activities in humans and non-humans 
primates. 
Non-human primates are particularly useful models for studies in which the physical activity is 
involved, because of the diurnal patterns of activity similar to the one in humans, but it’s not 
easy to determinate the total amount of energy expenditure that non-humans primates spend 
leaving in cages with regular tests such as DLW and indirect calorimetry either for the high cost 
of the treatments that for the high qualifications of the personal involved in the procedures.  
To overtake this problem several factories developed devices able to quantify the total 
movements of the body by 3-ways accelerometers or using multi-sensor activity monitors to 
have an esteem of energy expenditure in free living activities. 
Accelerometers (64, 65, 75) are useful to estimate the energy expenditure without interfering 
significantly in the normal life of the non-human primates. They are used to minimize the 
external agents, like different cages and different procedure, that can affected the normal 
behavior of the non-human primate.  
Classic techniques have been employed in non-human primates. The indirect calorimetry was 
performed by a modified metabolic chamber for non-human primates useful to determinate the 
gas exchange in O2 and CO2 during different type of exercises (53, 60, 64, 77-80) with the 
additionally calculation of the Respiratory Quotient ratio (81) as well as the DLW method  (54). 
In a recent study Papailiou et al. (65), used an accelerometer placed in a collar to detect activities 
that involve the whole body in non-human primates (rhesus monkeys) living in cages. The study 
demonstrated that the accelerometer is a useful tool for quantifying whole body movements in 
non-human primates, but it is not possible to detect the amount of energy expenditure for the 
various behaviors such as chewing and arm movements, only the total energy expenditure was 
calculated with this device. Additional studies were performed in rhesus monkeys by Sullivan et 
al. (82) and Hunnell et al. (64) and in Marmosets (75). 
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In all the studies considered, researchers used different type of exercise and different protocols to 
evaluate the energy expenditure; studies conducted in non-human primates included three 
different types of aerobic exercise: running, biking and climbing. 
Running on a treadmill and biking on a cycle-ergometer in humans are very common method to 
evaluate the level of fitness and to training people. 
This kind of exercise were also used in non-human primate study; Edgerton et al. (83) in his 
study trained 11 Galago senegalensis for 6 months to run upright rather than on 4 limbs on a 
treadmill to achieve a 60 min exercise at 43 m/min up to 4
th
 grade of inclination. After the 
training they continue to determinate the differences in muscle properties and structure involved 
in the exercise training. Also Rhyu  (84) in a study on the effect of an aerobic exercise training 
on cognitive functions, employed 12 Cynomolgus monkeys. They were divided in 3 different 
groups with a different workload and trained 4 of them to run on a treadmill for 1 h a day, 5 days 
a week for 5 months at the 80% of maximal aerobic power. In addition Ivy et al. (85) evaluated 
the adaptations by 18 baboons during low to moderate quadrupedal walking exercise on a 
motorized treadmill. 
Another type of exercise used to trained non-humans primates was developed by Hohimer et al. 
(78, 79) by using a modified chair-ergometer with a special metabolic chamber included. He 
performed on non-human primates, a dynamic leg exercise using a restrained chair during 
different exercises observing with dissimilar methods the regional blood flow distribution during 
the exercise in diverse region on the body. 
In additional studies researchers used a different method to achieve the same effect of an aerobic 
training such as running or biking utilizing the forearm and climbing skill to do that. 
Talan et al. (77) in his study trained 3 Macaca mulatta to lift weights repeatedly and Bourrin et  
al.  (86) trained 5 rhesus monkeys to execute a rope-climbing exercise for 1 h a day for 5 months, 
the work was focused to bone mass and bone cellular variations; it showed that this kind of 
aerobic exercise decrease bone volume and bone formation activity in non-human primates. 
Also Zerath (87) trained 5 males Rhesus macaca to practice 1h a day climbing in continuous for 
5 months to perform an endurance training to demonstrate the changes in bone mass in response 
to intense aerobic exercise. 
Different levels of physical activity are very important in every period of the life to maintain our 
body in healthy conditions. It’s essential to establish the minimal level of activity that people 
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should perform to be fit, but it’s also very important to quantify why in aging for example the 
physical activity decline, which are the mechanism involved. 
Ingram D. (88) and Sallis (89) in different works analyzed the decline in physical activity with 
age using non-human primates like a model.  
Researchers have shown that the age-related decline in activity is observed across a wide range 
of non-human species and this decline seems to be a predictive factor of lifespan (49, 88, 89).   
Epidemiological studies have noted the general decline in physical activity with advancing age 
and that it is generally greater for males than female subjects. It has also been shown in different 
studies that age is inversely associated with physical activity in studies with children, adolescent 
and adults. Until now scientists found that the decline in physical activity in humans is greater in 
males than females especially in the teen years (13-18 year old). 
To further understand these arguments scientists have developed different animal models for 
establishing dose-response relations for various physiological outcomes that could then be 
further tested and validated in humans. 
Physical activity has been demonstrated to produce benefits on human brain functions, 
influencing brain volume and in the cognitive performances, but the mechanisms involved 
cannot be easily tested in humans. Rodent models have been established in order to examine the 
effect of the physical activity on brain structure and functions. Chronic exercise increase the 
vascular volume fraction in different areas of the cortices and striatum, and increase blood flow 
in the cerebellum (84).  
A similar scientific question was asked in non-human primate, cynomolgus monkeys were 
trained to run on the treadmill to improve their fitness condition, in order to examine the effect of 
the exercise on the CNS.  
Using non-human primates allowed scientists to standardize and control all of the different 
factors that can be involved like exercise regimen and lifestyle factors such as diet, stress 
exposure etc. that cannot be controlled in humans. 
Rhyu (84) in his study tested if the regular exercise can help to improve cognitive functions. The 
exercise regime was the same used in humans, proposed by the American College of Sports 
Medicine and the American Heart association to improve the level of fitness, in which the 
subject should run at  80% of the own maximal aerobic capacity. Starting at the 9th week of 
training, were performed cognitive tests to prove the rate of learning and check how the blood 
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flow in the brain vary with a regular exercise. This study showed that a regular exercise program 
at a certain level improved rate of learning and vascular density in the brain in non-human 
primate.    
During exercise there are physiological changes in the blood flow distributions on the different 
parts of the body. 
Baboons, better that other animal model, such as dogs, show interesting similarities in 
redistribution of cardiac output. Hales et al. (90) tested in awake heat-stressed baboons the 
difference in blood flow to most of the major organs. Despite small differences he concluded that 
the splanchnic and renal vasoconstrictions between humans and non-human primates during heat 
stress in similar in magnitude.  
Slightly  different were the results in  Vatner et al. (91) study, in which non uniform responses in 
blood redistribution in mesenteric and renal flow during exercise and excitement in non-human 
primates, were found. 
Afterwards Hohimer (79) studied the variation of renal blood flow during a mild dynamic leg 
exercise in 12 baboons, confirming the previous findings in which baboon shows a decrease 
renal blood flow during exercise. In a second study (78) he extended the blood redistributions to 
several organs and tissues and concluded that baboons is a very is a useful animal model to 
investigate the different responses of  different tissues during exercise  
An additional remarkable field in which baboons are very good model is the osteoporosis 
because they have a bone metabolism and endocrine physiology similar to humans (56, 86, 87).  
Aufdemorte et al. (57) analyzed in different pilot studies the differences in bone density between 
young and aged female baboons using different techniques (radiograph exams, dual X-ray 
absorptiometry, the histomorphometric analysis, oral bone exams).  
They found dramatic differences in bone mass and volume between the two groups, the 
conclusion was that osteoporosis and oral bone loss in correlated with ovarian dysfunctions. This 
linkage found in this study was studied also in humans, with similar results. 
Also Zerath (87) focused his work to demonstrate the changes in bone mass due to intense 
aerobic exercise. 
Future studies involving genetic factors may help identify genes that can influence the 
development of the osteopenias in humans (56). 
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Non-humans primates are a very good model for gynecological physiology (53, 64). Different 
physiological mechanisms can be affected by incorrect behaviors and can lead to reproductive 
dysfunctions.  
In her study Williams et al. (53) suggest that a key role in exercise-associated menstrual 
disorders (EAMD) is the balance between energy intake and energy expenditure. 3 Macaca 
fasicularis were trained to run on a treadmill progressing up to 30 min a day, 7 day a week at 12 
km/h to determinate the effect of a very heavy training on the onset of amenorrhea (53). 
Hunnell et al. (64) checked if the physical activities differ over the menstrual cycle in 7 adults 
rhesus monkeys recording, using an accelerometer, the activity for several days; results showed 
that there is no changes across the menstrual cycle in physical activity.   
Sullivan et al. in his study (82) tried to determinate if there is a correlation between the weight 
gain in adulthood and the level of activity. In this study he tested 18 adult female rhesus 
monkeys during a 9 months period controlling 4 important parameters such as weight, food 
intake, level of physical activity and the resting metabolic rate. 
During all the period the activity level was measured with a 3-way accelerometer worn on the 
collar, the food intake was calculated for each meal and the weight was recorded every week. 
The rest metabolic rate was monitored at the beginning and after 3 months placed the monkey in 
a metabolic chamber. 
Results suggest a very strong correlation between the individual activity level and the tendency 
to gain weight; higher is the level of physical activity lower is the weight gain. 
This study support the data showed also in humans in whom a high level of physical activity 
prevent or limit weight and fat gain. 
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5.3 SUMMARY 
The baboon is a well-established and valuable non-human primate model for the study of 
multiple human chronic diseases. Currently, the model is subject to intensive research in order to 
elucidate common underlying mechanisms responsible for human metabolic diseases and the 
effect of novel pharmacological intervention in the common intricate pathophysiology of obesity, 
diabetes and the metabolic syndrome.  Use and demand of non-human primates has increased in 
recent decades and several models including baboons have been studied for this purpose with 
different approaches. 
Not surprisingly, accumulating research has shown that metabolic variables both at resting and 
after exercise, as well as the molecular signaling in adipose tissue and skeletal muscle in baboons 
highly resemble those in humans, thus providing a natural model for the study of exercise and its 
effect on adipose tissue, heart, lungs, bone and skeletal muscle metabolism, as well as the 
fascinating interaction between the “fit” body and the brain. 
With the recent identification of newer signaling pathways and molecular targets (i.e. TLR4, 
NFkB, AMPK) (63, 92-95) that can be modulated by exercise, and the development of novel 
pharmacological agents designed to enhance the molecular signaling exerted by physical activity, 
there is an increasing potential for the use of non-human primates as a research model.  The 
inherent morphologic and metabolic characteristics of baboons in combination with improved 
sensing devices for energy expenditure measurement make them an attractive and valuable 
model in the future to study the integration between the molecular signaling in skeletal muscle 
and other metabolically active tissues during physical activity and its correlation with metabolic 
variables obtained in living conditions. 
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6. ENERGY EXPENDITURE IN NON-HUMAN PRIMATES 
 
6.1 INTRODUCTION 
 
The precise evaluation of Energy Expenditure (EE) during free living conditions is important in 
order to prevent and manage the increasing sedentary lifestyle (96). In fact, physical inactivity is 
the fourth leading cause of death worldwide and a critical determinant of many chronic 
pathological condition such as obesity, insulin resistance and type 2 diabetes mellitus , among 
others (97, 98). 
The gold standards for measuring Resting Energy Expenditure (REE) and Total Energy 
Expenditure (TEE) in free living conditions are Indirect Calorimetry (IC) and the Double 
Labeled Water (DLW) techniques, respectively. These techniques are quite elaborate, expensive 
and can be performed only in few selected centers around the World.  
Questionnaire, pedometers and accelerometers were the first alternative methods used to have an 
accurate and reliable assessment of EE during physical activity (99-101). 
The next generation of these devices is represented by multisensory activity and lifestyle 
monitors that provide an estimate of REE and TEE and improve the measurement of the physical 
activity by using different algorithms. 
SenseWear® Armband (SWA; BodyMedia, Inc., Pittsburgh, PA) is a multisensory activity 
monitor. The device is typically worn on the upper right arm and provides estimation of TEE 
during free living based on a biaxial accelerometer, the galvanic skin response and the body heat 
loss. 
SWA has been validated in different populations including adults (102-106), children (107-109) 
and patients affected by different diseases (110-114),  both during resting (29, 104, 106, 115) as 
well of different intensity physical activities (116-121). 
The non-human primate is a valuable animal model in biomedical research, thanks to its close 
phylogenetic proximity to humans.  We have previously demonstrated that baboons display most 
if not all the critical pathophysiological and molecular alterations that are typically seen in 
obesity, insulin resistance, and T2DM in humans (9-11, 122-125).  
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In this study, we assessed in non-human primates, baboons, the REE and TEE by using a new 
activity monitor called SWA. In humans, SWA is generally placed on the arm, but this body site 
cannot be used in baboons as they would remove it, in few minutes.  
To overcome this problem, we previously demonstrate the reliability of SWA placed the back 
(latissimus dorsi muscle) in humans and then test the SWA on baboons, in the back, after 
mounting it in a special jacket that would prevent the animals to remove it.  
Therefore, the objectives of this study was evaluate REE and TEE in free living condition in 
baboons over a period of 6 days with the SWA placed on the latissimus dorsi muscle in a special 
jacket. 
6.2 MATERIALS AND METHODS 
SenseWear Armband® (SWA) is a wireless multisensory activity monitor; it is normally worn 
on the upper right arm over the triceps muscle, halfway between the acromion and olecranon. 
The SWA collects and processes a variety of physiological data through multiple sensors I): a 
two-axis accelerometer; II): heat flux sensor; III): skin temperature sensor; IV): near-body 
ambient temperature sensor; V): galvanic skin response sensor that can then be uploaded and 
analyzed using a computer software called InnerView Research Software (InnerView Research 
Software 6.1; BodyMedia Inc, Pittsburgh, PA, USA) (Figure 6.2.1). 
 
 
Figure 6.2.1. An image of the SenseWear® Armband (SWA). 
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6.3 NON-HUMAN PRIMATES (BABOONS) SUBJECTS 
Twenty one baboons (Papio hamadryas), 8 females and 13 males were involved in this study. In 
order to get anthropometric measurement in the baboons, they were sedated and then weight 
(kg), height (m) and waist circumference (m) were measured, BMI was calculated as weight 
(kg)/stature (m
2
); all the anthropometric characteristics are reported in Table 6.3.1. 
 
Primates Total n=21 Female n=8 Male n=13 
  mean ± SD mean ± SD mean ± SD 
AGE (years) 12.2 ± 3.8 15.1 ± 3.2 10.5 ± 2.9 
HEIGHT (m) 1.0 ± 0.1 0.9 ± 0.1 1.1 ± 0.1 
WEIGHT (kg) 27.0 ± 7.4 18.8 ± 0.8 32.1 ± 4.2 
WAIST 
CIRCUMFERENCE (m) 
0.6 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 
BMI (kg/m
2
) 24.8 ± 4.4 21.5 ± 2.4 26.8 ± 4.1 
Table 6.3.1. Descriptive characteristics of the baboons (n=21). 
 
6.4 EVALUATION OF FREE LIVING ENERGY EXPENDITURE IN NON-HUMAN 
PRIMATES  
Since it is not possible to keep the SWA on the arm of the baboon because of their innate 
curiosity and tendency to remove the device, we placed the metabolic holter in a specially 
designed “metabolic jacket” (Figure 6.4.1) , modified from the one used in the tether system of 
the baboon that has a slit in the back allowing the placement of the SWA to be in contact with 
the skin of the baboon’s lumbar area on the latissimus dorsi muscle (126). 
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Figure 6.4.1. Metabolic jacket for energy expenditure measurement in baboons. Device is customized to fit a preset 
SWA in each baboon’s back in order to continuously record energy expenditure over a week (left side). Installation 
of a metabolic jacket in baboons (right side); in order to ensure continuous reading and data recording a direct and 
firm contact with the skin is critical. 
We tested the SWA placed in a special jacket in 21 baboons (n= 8 females, n= 13 males) (Figure 
6.4.2). 
 
Figure 6.4.2. Metabolic jackets can be customized and adjusted to different sizes based on 
baboon gender (Red and white for female; black and with for male), size and age. 
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In the first day, the animals were sedated, weight (kg), height (m) and waist circumference (m) 
were measured and all the needed data inserted in the InnerView Research Software in order to 
set the SWA before placing it on the jacket.   
All animals were housed in a single cage, for 1 week with ad libitum access to water and food 
(500 g of chow daily plus enrichment such as grains, various kind of fruits and vegetables, 
peanut butter, dry fruit, honey, cereal, and frozen yogurt).The standard chow contained 57.7% 
carbohydrates, 15.3% protein, and 4.7% fat (Monkey Diet 15%, Purina 5LE0; TestDiet; 
Richmond, IN). Enrichment games were constituted by videos and balls. 
Baboons were sedated with ketamine to allow placement of the jacket with the embedded 
activity monitor. Animals were observed twice daily for any clinical or behavioral abnormalities 
which includes pain or discomfort. Each animal assigned to the study was acclimated to the 
jacket.  Only animals that would accommodate the jackets were selected.  
After placement of the metabolic jacket, they were returned to their cage and observed until 
recovered. The animals were also checked for potential signs of skin irritation produced by the 
jacket. There were no signs of pain or discomfort produced by the jacket throughout the study 
period.  
After 6 days the animal were sedated again and the jacket with the SWA removed, and the data 
downloaded.  
We evaluated also a REE on 30 min period in which the baboon was not moving and the light 
was off, and the percentage of contact of SWA with the body surface was 100%.  
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6.5 ETHICS STATEMENTS 
Experimental protocols were approved by the Institutional Animal Care and Use Committee 
(IACUC) of the Texas Biomedical Research Institute and the University of Texas Health Science 
Center San Antonio and conformed to the current guidelines of the National Institutes of Health 
for the care and use of laboratory animals.  
6.6 STATISTICAL ANALYSIS 
Statistical analysis was performed with GraphPad 5.01 (GraphPad Software, Inc.). The Bland-
Altman bias plots were used to assess the agreement between the IC measurement and the SWA 
estimation (placed in the upper right arm and around the waist in the lumbar zone) during resting 
and activity. The limit of agreement (LOA) involved the mean difference between the two 
measurement tools ± 1.96 SD of the differences. 
Pearson’s correlations were also used to analyze the correlation between the EE data provided by 
the SWA, placed on the arm or the back, and IC. Statistical significance was defined at p<0.05 
and data are shown as mean ± standard deviation (SD) or mean ± standard error (SE).  
6.7 RESULTS 
In the study we compared the data, provided by SWA placed in the metabolic jacket, during 
resting and during free living condition in baboons all together and divided by gender. 
During the resting part the mean EE was 0.537 ± 0.009 kcal/min for all the animals, 0.625 ± 
0.005 kcal/min for males and 0.367 ± 0.007 kcal/min in females. 
The total energy expenditure (TEE) has an overall mean of 0.82 ± 0.06 kcal/min, 0.89±0.06 
kcal/min for male, and 0.68±0.07 kcal/min for female (Figure 6.7.1). 
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Figure 6.7.1. Baboon Activity (Total Energy Expenditure [TEE] [kcal/day]) and Resting (Resting Energy 
Expenditure [REE] [kcal/day]). Plots of mean Energy Expenditure (kcal/min) during resting and activity in female 
(A), male (B) and in all the baboons (C). 
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6.8 DISCUSSION 
A large variety of studies have been performed to test the reliability of the SWA  by estimating 
EE during resting and physical activity and comparing the results with DLW (99, 102, 103, 127), 
IC (104-109, 111-117, 120), accelerometers and pedometers (74); in controlled situation and in 
free living conditions  (102, 105). 
In this study we explored the feasibility to register the EE in baboons placing SWA in a special 
metabolic jacket for 6 days in free living condition.  
In this clinical context, the measurement of the basal metabolic rate can also be important, for 
example, to provide optimal nutritional support in critical patients. 
This study was focused on the adaptation of the SWA in the metabolic jacket for the baboons 
and measuring energy expenditure during 6 days of free living condition. 
We believe that it is interesting to show that this device can be used also in non-humans primate 
and SWA is able to detect differences in EE during resting and physical activity, also if the EE is 
very low due to small space (cage) where baboons were placed. 
There are very few studies in literature about the daily energy expenditure of baboons. 
Rosetta and collaborators measured with DLW, the total EE and compared the variations 
between two different periods of life, early lactation and after the resumption of sexual cycling, 
in 8 female baboons (Papio anubis); 24 hours total EE was determined over a 4-day period; the 
average TEE was 3.49 MJ/d in the first period and 3.48 MJ/d in the second (128).  
Leonard and collaborators examined the variations in metabolic requirements among extant 
primate species based, Papio anubis,  the Resting Metabolic Rate (RMR) was 956 kcal/d for 
male and 520 kcal/d for female; the TEE was 1281kcal/d for male and 699 kcal/d for female 
which are in agreement with our estimated EE employing the SWA (129). Table 6.8.1 has been 
included to facilitate the comparison between the present study and the two previously published 
studies (128, 129).   
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TEE (kcal/day) REE (kcal/day) Method 
 
Male Female Male Female   
Present study 1267 936 893 533 
SenseWear Armband® 
(SWA) 
Rosetta et Al. 
(40) N/A 833 N/A N/A 
Doubly Labeled Water 
(DLW) 
Leonard et Al. 
(41) 1281 699 956 520 
Indirect Calorimetry + 
Estimation by Equations 
(Kleiber and Leonard) 
N/A = Data Not Available 
Table 6.8.1 Comparison of Total Energy Expenditure (TEE) data (kcal/day) and Resting Energy Expenditure Data 
(REE) data (kcal/day) between three different studies in non-human primates. 
 
In conclusion, these studies demonstrate that the SWA is a reliable and simple method to 
estimate TEE and REE in non-human primate, baboons, by placing it in the “metabolic jacket”. 
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7. BABOONS AND EXENATIDE 
7.1 RESEARCH DESIGN AND METHODS 
7.1.1 STUDY POPULATION 
Twenty eight female (Papio hamadryas) non-diabetic baboons were selected from the colony in 
the Southwest National Primate Research Center at Texas Biomedical Research Institute (San 
Antonio, TX) by following the selection criteria reported in a previous study (10).  Each animal 
was housed in a single cage with ad libitum access to water and food (standard chow containing 
57.7% carbohydrates, 15.3% protein, and 4.7% fat- Monkey Diet 15%, 5LE0; TestDiet; 
Richmond, IN). The amount of food consumed by each animal was registered daily. 
Experimental protocols were approved by the Institutional Animal Care and Use Committee 
(IACUC) of the Texas Biomedical Research Institute and the University of Texas Health Science 
Center San Antonio and conform to the current guidelines of the National Institutes of Health for 
the care and use of laboratory animals. 
7.1.2 STUDY DESIGN 
Prior to treatment baboons underwent a body composition analysis and long-term catheterization 
for blood collection and drug infusions by placing heparin-coated polyurethane catheters in the 
internal jugular vein and carotid artery. Catheters were routed subcutaneously to the mid-
scapular region where they were connected to the tether jacket chronic infusion system (126). 
Three days after catheterization, the 1st 2-step hyperglycemic clamp (HC) was performed 
followed by a partial pancreatectomy (PPx) removing the tail of the pancreas.  After a 96-hrs 
recovery period on total parenteral nutrition, baboons were fed again with standard chow and 
randomly divided into 3 study groups: (i) PPx-Exenatide-treated (n=12); (ii) PPx-Saline-treated 
(n=12), and (iii) Sham-saline-treated (n=4).  At the end of treatments, after a 72-hour wash-out 
period, baboons underwent a 2nd body composition analysis and a 2nd 2-step HC.  Baboons 
were then euthanized and the remnant pancreas removed (Figure 7.1.2.1). 
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Figure 7.1.2.1.Design of the study. 
 
7.1.3 BODY COMPOSITION ANALYSIS 
All baboons underwent a dual-energy X-ray absorptiometry (DXA) scan (Lunar Prodigy 
densitometer; GE Healthcare, Madison, WI) to determine fat-free mass (FFM), fat mass (FM), 
percent body fat (%BF). Scanning was performed on ketamine-sedated animals and data were 
obtained by using the software Encore2007 (GE Healthcare, Madison, WI). Animal were placed 
in a supine position during the scan. 
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7.1.4 HYPERGLYCEMIC CLAMP 
After an overnight fasting, baboons were sedated with ketamine hydrochloride (10 mg/kg i.m.) 
and endotracheal intubation was performed using disposable cuffed tubes (6.5-8.0 mm diameter) 
under direct laryngoscopic visualization. Oxygen was given (98-99.5% FiO2) to keep the oxygen 
saturation > 95% and deep anesthesia induced by using a mix of oxygen and inhaled isofluorane 
(0.5-1.5%). After animal stabilization, a 2-step HC was performed as originally described (130). 
Briefly, a bolus of 50% dextrose (Dextrose 50%, Hospira, Lake forest, IL) solution was 
administered and followed by a continuous infusion of 20% dextrose (Dextrose 20%, Baxter, 
Deerfield, IL). The rate of infusion was calculated to raise and maintain plasma glucose 125 
mg/dL above basal. After 90 min, the infusion rate was increased to achieve the second 
hyperglycemic step [(FPG + 125 mg/dl) + 100 mg/dl] which was steadily controlled until the end 
of the experiment.  At time 180 min, an Arginine bolus (10% Arginine Hydrochloride, Hospira, 
Lake Forest, IL) was administered. Blood samples were collected in EDTA tubes supplemented 
with 100 µL of Aprotinin. Glucose was measured by using a Glucose Analyzer (GM9 Glucose 
Analyzer, Analox Instruments USA Inc, Lunenburg, MA) and insulin, glucagon and C-peptide 
by RIAs.  
7.1.5 PARTIAL PANCREATECTOMY (PPx)   
A midline epigastric incision was performed and followed by standard surgical procedures for 
entering into the abdominal cavity. The free portion of the greater omentum was retracted 
cranially and the omental leaf bluntly separated to allow direct visualization of the left pancreas. 
PPx was obtained using the suture fracture technique by making an incision on the 
mesoduodenum or omentum on each side of the pancreas to mark the portion of it to be removed. 
Pancreas was then ligated immediately proximal to the marks and the distal part, accounting for 
~ 30% of the whole organ, was excised. Holes in the mesoduodenum and omentum were sutured 
with absorbable material and the abdominal cavity closed. After surgery, baboons underwent a 
96-hrs recovery period on total parenteral nutrition (TPN). Baboons of the sham (SHAM) group 
did not undergo surgery. 
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7.1.6 TREATMENT 
By using the tether system (126) the baboons were chronically infused intravenously for 13 
weeks with either saline (SAL and SHAM groups) or Exenatide (Byetta, Amylin 
Pharmaceuticals, San Diego, CA) (EXE group) at the dose of 0.014 µg/kg/h. To allow for 
continuous infusion via the tether system, exenatide was diluted in normal saline.  
7.1.7 CALCULATION INSULIN SECRETION RATE, INSULIN SENSITIVITY AND 
DISPOSITION INDEX  
Insulin sensitivity was calculated by M/I index (130) where M is the glucose infusion rate 
registered during the hyperglycemic clamp and I is the insulin concentration in the same period 
analyzed for the M , (150-180 min); is a measure of the quantity of glucose metabolized per unit 
of plasma insulin concentration . 
The disposition index (DI) is the measure of the ability of the β-cell to compensate for insulin 
resistance; it is calculated multiplying area under the curve of the insulin in the first phase  (AUC 
Insulin (0-12) ) by the insulin sensitivity calculated as a M/I index [AUC Insulin (0-12) * M/I]  
(131).  
7.2 STATISTICAL ANALYSIS 
Statistical analysis was performed with Stata/SE Version 11.2 (Stata Corp LP, College Station, 
TX) using non-parametric tests due to a small sample size (n=27). The Wilcoxon rank test was 
used to make comparisons between groups expressed as percent differences. The Wilcoxon 
signed-rank test was used for the analysis of the changes from baseline to end of the study. All 
data were expressed as mean ± SE and statistical significance set for p<0.05. Statistical analysis 
was performed in collaboration with the Department of Epidemiology and Biostatistics at the 
University of Texas Health Science Center San Antonio. 
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7.3 RESULTS 
7.3.1 BODY COMPOSITION ANALYSIS 
Total body weight, lean and fat mass were assessed by DXA at the beginning and end of the 
study.  A significant reduction in fat mass was observed in both EXE and SAL-treated baboons 
(EXE, from 1.54 ± 0.45 to 0.93 ± 0.2, p=0.04; SAL, from 1.27 ± 0.24 to 0.86 ± 0.21 kg, p=0.05) 
while not in the SHAM group A slight but significant decrease in total body weight (SAL, 18.5 ± 
0.7 to 16.7 ± 0.7 kg, p=0.01; EXE 18.2 ± 0.8 to 17.2 ± 0.6 kg, p=0.08) and lean mass (SAL 16.1 
± 0.5 to 15.0 ±0.6 kg, p=0.03; EXE 15.6 ± 0.4 to 15.2 ± 0.5 kg, p=0.24) was observed only in 
SAL-treated baboons. The consumption of food during the 13 weeks of treatment in all the three 
groups was similar and stable (Figure 7.3.1.1). 
 
Figure 7.3.1.1. Body composition of all the baboons (n=28) at the beginning (black bars) and at the end of the study 
(white bars), divided by treatment (Exenatide [n=12], Saline [n=12] and Sham [n=4]). A, fat mass (kg), B, lean 
mass (kg) and C, total body weight (kg). All these data were obtained by DXA. D, average food consumption 
(Kcal/day/kg of body weight) in the three different groups, during 13 weeks of treatment.  
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7.3.2 SECRETION 
 
All three groups show a slight increase in the area under the curve (AUC) for glucose during the 
2nd 2-step HC performed after treatment with EXE or SAL. Differences were not significant in 
the SAL- (from 54166 ± 863 to 55969 ± 1234, p=0.21) and SHAM-groups (from 55901 ±790 to 
56814 ± 1488, p=0.72); however, there was a statistically significant difference in EXE-treated 
baboons (from 53697 ± 711 to 57792 ± 1360, p=0.05).   
 
Figure 7.3.2.1. Glucose secretion in the three different groups: Exenatide (A), Saline (B) and 
Sham (C). 
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A marked decrease in the AUC for insulin secretion was observed in the EXE group (from 29243 
± 5842 to 16910 ± 3432, p=0.02), in contrast, insulin secretion remained stable in SAL (from 
16399 ± 2319 to 16862 ± 3537, p=1) and SHAM (from 29713 ± 2957 to 37993 ± 12849, 
p=0.47). 
 
Figure 7.3.2.2.   . Insulin secretion in the three different groups: Exenatide (A), Saline (B) and 
Sham (C). 
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 As expected, AUC for C-peptide secretion showed the same pattern reported for insulin with a 
significant decrease only in the EXE group (from 2139 ± 225 to 1654 ± 221, p=0.01) while in 
SAL (from 1666 ± 159 to 1574 ± 141, p=0.53) and SHAM (from 2296 ± 147 to 2675 ± 425, 
p=0.47) remained stable.  In EXE-treated baboons, AUC for insulin and C-peptide secretion was 
also significantly decreased in response to acute L-arginine stimulation (180-210 min), while not 
in the other groups.  
 
Figure 7.3.2.3.  . C peptide secretion in the three different groups: Exenatide (A), Saline (B) and Sham (C). 
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Finally, a small non-significant increase in the AUC for glucagon secretion was observed in all 
groups (EXE, from 5946 ± 602 to 6446 ± 576,p=0.58; SAL, from 5871 ± 904 to 6362 ± 876, 
p=0.66; SHAM, from 8040 ± 73 to 7724 ± 869, p=0.72) (Figure 7.3.2.4). All the data are 
represented in Figure 7.3.2.5. 
 
Figure 7.3.2.4.  . Glucagon secretion in the three different groups: Exenatide (A), Saline (B) and Sham (C). 
 
 
44 
 
 
Figure 7.3.2.5 Area under de curve (AUC) evaluation in all the three groups: Exenatide, Saline and Sham, for 
glucose (A), insulin (B), c-peptide (C) and glucagon (D) secretion. 
In EXE-treated baboons was showed a remarkable increase in tissue insulin sensitivity calculated 
by the M/I index (from 17.1 ± 3.1 to 28.9 ± 4.2, p=0.01) (Figure 7.3.2.6 B). Conversely, insulin 
sensitivity did not change significantly in SAL (from 33.2 ± 9.2 to 26.8 ± 4.4, p=0.86) and 
SHAM (from 11.1 ± 1.6 to 10.2 ± 2.3, p=0.72).  
Calculation of the β-cell function by using the Disposition Index (DI) showed a significant 
increase in the EXE (from 84 ±8 to 169 ± 16, p= 0.01), a small non-significant increase in SAL 
(from 125 ± 19 to 151 ± 20, p=0.37) and an insignificant decrease in SHAM (79 ± 29 to 63 ± 19, 
p=0.14) (Figure 7.3.2.6 C).    
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Figure 7.3.2.6. Insulin sensitivity (M/I) [A] and disposition index (DI) [B] calculated by AUC of insulin between 0 
to 12 minutes multiply by M/I. All the baboons (n=28) are divided by treatment (Exenatide, Saline and Sham); black 
bars represent data at the beginning of the study and white bars represent data at the end of the study. 
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In conclusion, baboons treated with EXE showed a dramatic increase in insulin sensitivity 
reflecting an improvement in the global β-cell function (or performance) as compared to SAL-
treated and SHAM. 
7.4 DISCUSSION 
The major unpredicted finding of this study is the demonstration of the powerful, direct, insulin 
sensitizing effect of EXE on normal glucose tolerant baboons after partial pancreatectomy.  The 
enhancement of insulin action is not considered amongst the main mechanisms of action of GLP-
1 receptor agonists although early pioneering studies have shown that GLP-1 increases 
significantly insulin sensitivity in both T2DM and T1DM subjects (132). Thus far, the increased 
insulin sensitivity commonly observed in subjects treated with GLP-1 receptor agonists, has been 
considered secondary to the decrease in circulating glucagon levels and body weight (133).  Yet, 
indication that EXE can improve insulin sensitivity independently from changes in body weight 
has been already provided in both rodents and humans (42, 134, 135).  In the present study, 
treatment with EXE and SAL induced similar effects on body fat mass and circulating glucagon 
levels suggesting that the increased insulin sensitivity observed with EXE must be due to a direct 
insulin potentiating effect of this drug.  Indeed, acute EXE administration in dogs, sensitizes 
insulin-mediated whole body glucose disposal and promotes the uptake of exogenous glucose by 
the liver (136). The mechanisms mediating the insulin mimetic activity of EXE are currently 
under investigation. 
At the start of the study, baboons underwent a partial pancreatectomy (PPx) that consisted in the 
removal of part of the pancreatic tail that accounted for by ~ 30% of the whole organ mass.  
Previous studies in primates and humans have shown that more than 50% of the pancreas mass 
must be excised to induce hyperglycemia or to increase the risk of developing diabetes (137-
139).  As we were not interested with studying the effects of an acute increase in the functional 
demand on the remnant pancreas, we merely harvested a mass of tissue large enough to allow 
reliable histopathological comparisons of islets morphology before and after treatments.  
Surprisingly, however, in spite of the marginal mass of tissue removed, PPx induced a small 
increase in fasting glucose levels that reached statistical significance in EXE-treated baboons but 
that was also evident in the control group.  Hyperglycemic clamps also showed a modest 
increase in glucose (AUC glucose). In EXE-treated baboons, this modest increase in AUC 
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glucose was associated with a remarkable decrease in insulin and C-peptide secretion in response 
to both glucose and arginine.  To our knowledge this is the first report that shows an inhibitory 
effect of EXE on insulin secretion.  The underlying reason EXE-treated baboons showed a small 
but significantly higher fasting glucose and increased AUC glucose during the clamps remains to 
be explained.  Perhaps, the striking decrease in insulin secretory demand that EXE induced in 
these baboons is due to quiescent β-cells.  Dormancy is a recently recognized β-cell state, far 
from simple rest, that follows a vigorous decrease in β-cell functional demand such as can be 
achieved after pancreas transplantation in normoglycemic recipients (140).  Dormant β-cells 
constitute a functional reserve but the cellular machinery involved in the exocytosis of the insulin 
granules might be less reactive than normal accounting for the slight increase in plasma glucose 
levels in response to acute supraphysiologic stimulations. Whether confirmed in humans, the fact 
that EXE might induce β-cell rest or dormancy is extremely appealing as resting diminishes β-
cell immunogenicity (141) and renders β-cells less vulnerable to the major cytotoxic insults 
involved in the pathogenesis of T1DM and T2DM (32, 141-143).   
In conclusion, in a preclinical model with striking similarities to the human, EXE treatment 
induces a remarkable insulin sensitizing effect. This study provides novel solid foundation for 
further clinical trials aimed at preserving the β-cell mass in subjects with diabetes or at high risk 
of developing it. 
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7.5 TABLES AND FIGURES 
 
Table 7.5.1 Anthropometric characteristics of 28 baboons involved in the study.  
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